Hypoactive sexual desire disorder in women: Treatment options beyond testosterone and approaches to communicating with patients on sexual health

Pharmacotherapy

Volumn 33, Issue 4, 2013, Pages 411-421

  Lodise, Nicole M ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Hypoactive sexual desire disorder; Pharmacotherapy

Indexed keywords

AMFEBUTAMONE; ARGININE; ARGINMAX; BREMELANOTIDE; FLIBANSERIN; GINKGO BILOBA EXTRACT; LEPIDIUM MEYENII EXTRACT; MULTIVITAMIN; PLACEBO; PRASTERONE; SILDENAFIL; UNCLASSIFIED DRUG; YOHIMBINE;

ALTERNATIVE MEDICINE; ANDROGEN THERAPY; BEDTIME DOSAGE; BEHAVIOR THERAPY; DIET SUPPLEMENTATION; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEMALE; FEMALE SEXUAL DYSFUNCTION; HEALTH PERSONNEL ATTITUDE; HORMONAL THERAPY; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; INTERPERSONAL COMMUNICATION; LIFESTYLE MODIFICATION; NAUSEA; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; SCREENING TEST; SEXUAL HEALTH; SINGLE DRUG DOSE;

ALPHA-MSH; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BENZIMIDAZOLES; BUPROPION; COMPLEMENTARY THERAPIES; FEMALE; HEALTH BEHAVIOR; HEALTH COMMUNICATION; HUMANS; PEPTIDES, CYCLIC; PIPERAZINES; PURINES; RECEPTORS, MELANOCORTIN; REPRODUCTIVE HEALTH; SEROTONIN ANTAGONISTS; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SULFONES; VASODILATOR AGENTS;

EID: 84879526883     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1209     Document Type: Review

References (67)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition. Washington, DC: American Psychiatric Press, 2000.
2. American Psychiatric Association DSM-5 development. Available from http://www.dsm5.org/ProposedRevisions/Pages/ proposedrevision.aspx?rid=432. Accessed May 6, 2011.
3. Brock Woodis C, McLendon AN, Muzyk AJ. Testosterone supplementation for hypoactive sexual desire disorder in women. Pharmacotherapy 2012;32:38-53.
4. Clayton A. Epidemiology and neurobiology of female sexual dysfunction. J Sex Med 2007;4:260-268.
5. West S, D'Aloisio AA, Agans RP, Kalsbeek WD, Borisov NN, Thorp JM. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med 2008;168:1441-1449.
6. Shifren J, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol 2008;112:968-969.
7. Cain V, Johannes CB, Avis NE, et al. Sexual functioning and practices in a multi-ethnic study of midlife women: baseline results from SWAN. J Sex Res 2003;40:266-276.
8. Palacios S, Castano R, Grazziotin A. Epidemiology of female sexual dysfunction. Maturitas 2009;63:119-123.
9. Buffum J. Prescription drugs and sexual function. Psychiatric Med 1992;10:181-198.
10. Finger W, Lund M, Slagle MA. Medications that may contribute to sexual disorders. A guide to assessment and treatment in family practice. J Fam Pract 1997;44:33-43.
11. Feldhaus-Dahir M. The causes and prevalence of hypoactive sexual desire disorder: part I. Urol Nurs 2009;29:259-263.
12. Dove N, Wiederman MW. Congnitive distraction and women's sexual functioning. J Sex Marital Ther 2000;26:67-78.
13. Parish S. From whence comes HSDD. J Fam Pract 2009;58: S16-S21.
14. van Berlo W, Ensink B. Problems with sexuality after sexual assault. Annu Rev Sex Res 2000;11:235-237.
15. Weiderman M. Women's body image self-consciousness during physical intimacy with a partner. J Sex Res 2000;37:60-68.
16. Bachmann G. Female sexuality and sexual dysfunction: are we stuck on the learning curve? J Sex Med 2006;3:639-645.
17. Harsh V, McGarvey EL, Clayton AH. Physician attitudes regarding hypoactive sexual desire disorder in a primary care clinic: a pilot study. J Sex Med 2008;5:640-645.
18. Marwick C. Survey says patients expect little physician help on sex. JAMA 1999;281:2173-2174.
19. Clayton A, Goldfischer ER, Goldstein I, et al. Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009;6:730-738.
20. Derogatis L, Rosen R, Leblum S, et al. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. J Sex Marital Ther 2002;28:317-320.
21. Derogatis L, Clayton A, Lewis-D'Agostino D, et al. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008;5:327-364.
22. Leiblum S, Symonds T, Moore J, et al. A methodology study to develop and validate a screener for hypoactive sexual desire disorder in postmenopausal women. J Sex Med 2006;3:454-455.
23. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual dysfunction. J Sex Marital Ther 2000;26:191-208.
24. Rust J, Derogatis L, Rodenberg C, et al. Development and validation of a new screening tool for hypoactive sexual desire disorder: the Brief Profile of Female Sexual Function (B-PFSF). Gynecol Endocrinol 2007;23:638-644.
25. Taylor J, Rosen RC, Leiblum SR. Self-report assessment of female sexual function: psychometric evaluation of the Brief Index of Sexual Functioning for Women. Arch Sex Behav 1994;23:627-643.
26. Bradenburg U, Bitzer J. The challenge of talking about sex: the importance of patient-physician interaction. Maturitas 2009;63:124-127.
27. Sobczak J. Female sexual dysfunction: knowledge development and practice implications. Perspect Psychiatr Care 2009;45:161-172.
28. Berman JR, Berman LA, Toler SM, Gill J, Haughie S, Sildenafil Study Group. Safety and efficacy of sildenafil citrate for the treatment of female sexual arousal disorder: a double-blind, placebo controlled study. J Urol 2003;170:2333-2338.
29. Clayton A, Dennerstein L, Pyke R, Sand M. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Women's Health 2010;6:639-653.
30. DeRogatis L, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med 2012;9:1074-1085.
31. Diamond L, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006;3:628-638.
32. Goldfisher E, Breaux J, Katz M, et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): results from a randomized withdrawal trial. J Sex Med 2011;8:3160-3172.
33. Kaplan S, Reis RB, Kohn IJ, et al. Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. Urology 1999;53:481-486.
34. Nurnberg H, Hensley PL, Heiman JR. Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. JAMA 2008;300:395-404.
35. Safarinejad M. Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study. J Sex Med 2008;5:887-897.
36. Safarinejad M, Hosseini SY, Asgari MA, Dadkhah F, Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU Int 2010;106:832-839.
37. Segraves R, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004;24:339-342.
38. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012;9:793-804.
39. Model J, May RS, Catholic CR. Effect of bupropion SR on orgasmic dysfunction in nondepressed subjects pilot study. J Sex Marital Ther 2000;20:231-240.
40. Segraves R, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther 2001;27:303-316.
41. Meston C, Frohlich PF. The neurobiology of sexual function. Arch Gen Psychiatry 2000;57:1012-1030.
42. Meston C, Derogatis LR. Validated instruments for assessing female sexual function. J Sex Marital Ther 2002;28(s):155-164.
43. Derogatis L, Rust J, Golombok S, Kuznicki J, Rodenberg CA, McHorney CA. A patient-generated multinational inventory to measure distress associated with low desire (PDS ©). Atlanta, GA: International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting, 2004.
44. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil: a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996;78:257.
45. Berman JR, Berman LA, Lin H, et al. Effect of sildenafil on subjective and physiologic parameters of the female sexual response in women with sexual arousal disorder. J Sex Marital Ther 2001;27:411.
46. Brown D, Kyle JA, Ferrill MJ. Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction. Ann Pharmacother 2009;43:1275-1285.
47. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health, US Dept of Health, Education and Welfare, 1976.
48. Berman LA, Berman JR, Werbin T, Chabra S, Goldstein I. The use of the Female Intervention Efficacy Index (FIEI) as an immediate outcome measure of medical intervention to treat female sexual dysfunction. J Sex Marital Ther 2001;27:427.
49. Borsini F, Evans K, Jason K, Rhode F, Alexander B, Pollentier S. Pharmacology of Flibanserin. CNS Drug Rev 2002;8:117-142.
50. Stahl S, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med 2011;8:15-27.
51. DeRogatis L, Clayton A, Lewis D'Agostino A, Wunderlich G, Fu Y. Validation of the Female Sexual Distress Scale-Revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med 2008;5:357-364.
52. Shadiack A, Sharma SD, Earle DC, et al. Melanocortins in the treatment of male and female sexual dysfunction. Curr Top Med Chem 2007;7:1137-1144.
53. Aung H, Dey L, Rand V, Yuan CS. Alternative therapies for male and female sexual dysfunction. Am J Chin Med 2004;32:161-173.
54. Ito T, Trant AS, Polan ML. A double-blind placebo-controlled study of ArginMax, a nutritional supplement for enhancement of female sexual dysfunction. J Sex Marital Ther 2001;27:541-549.
55. Piletz J, Segraves KB, Feng YZ, Maguire E, Dunger B, Halaris A. Plasma MHPG response to yohimbine treatment in women with hypoactive sexual desire. J Sex Marital Ther 1998;24:43- 54.
56. Michelson D, Kociban K, Tamura R, Morrison MF. Mirtazapine, yohimbine, or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial. J Psychiatr Res 2002;36:147-152.
57. Rowland D, Tai W. A review of plant-derived and herbal approaches to the treatment of sexual dysfunctions. J Sex Marital Ther 2003;29:185-205.
58. Segraves R. Treatment-emergent sexual dysfunction in affective disorder. J Clin Psychiatry 1993;11:1-4.
59. Segraves R. Treatment of drug-induced anorgasmia. Br J Psychiatry 1994;165:554.
60. Berman JR, Berman LA, Werbin TJ, Goldstein I. Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol 1999;9:563-568.
61. Meston C, Worcel M. The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. Arch Sex Behav 2002;31:323-332.
62. Genazzani A, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661-668.
63. Labrie F, Archer D, Bouchard C, et al. Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 2009;16:923-931.
64. Meston C, Rellini AH, Telch MJ. Short and long term effects of ginkgo biloba extract on sexual dysfunction in women. Arch Sex Behav 2008;37:530-547.
65. Brooks N, Wilcox G, Walker KZ, Ashton JF, Cox MB, Stojanovska L. Beneficial effects of Lepedium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause 2008;15:1157-1162.
66. Greene JG. Constructing a standard climacteric scale. Maturitas 2008;61:78-84.
67. Laine H, Jones K. Hypoactive sexual dysfunction in a young woman. Obstet Gynecol 2007;109:415-418.